Ambrisentan tablets are indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
| Strength | 5mg |
| Pack Size | 3 x 10 Tablets |
| Packaging Type | Box |
| Form | Tablet |
| Compostion | Ambrisentan |
| Brand Name | Pulmonext |
| Prescription/Nonprescription | Prescription |
| Shelf Life | 2 Year |
| Manufacturer | MSN Pharma |
Ambrisentan tablets are indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
| Strength | 5mg |
|---|---|
| Pack Size | 3 x 10 Tablets |
| Packaging Type | Box |
| Form | Tablet |
| Compostion | Ambrisentan |
| Brand Name | Pulmonext |
| Prescription/Nonprescription | Prescription |
| Shelf Life | 2 Year |
| Manufacturer | MSN Pharma |
Reviews
There are no reviews yet.